Condition

Chronic Myelomonocytic Leukemia clinical trials and research

• 37Clinical trials
• 10NIH research projects
• 18Countries

Newest Chronic Myelomonocytic Leukemia clinical trials

All recruiting trials (37)

• Low-dose post-transplant cyclophosphamide plus tacrolimus and ruxolitinib to prevent GVHD after myeloablative peripheral blood stem cell transplant

  This test sees if adding low-dose post-transplant cyclophosphamide with tacrolimus and ruxolitinib can reduce severe acute graft-versus-host disease in adults receiving myeloablative peripheral blood stem cell transplants for leukemia or myelodysplasia.

  Recruiting at 3 sites Phase 2 Ohio State University Comprehensive Cancer Center · Birmingham, Alabama and 2 other locations · NCT07249346

• Momelotinib plus azacitidine for chronic-phase MDS/MPN and chronic neutrophilic leukemia

  This trial will test whether adding momelotinib to a standard hypomethylating drug helps adults with chronic-phase MDS/MPN or chronic neutrophilic leukemia control their disease and symptoms.

  Recruiting Early Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT07071155

• FLAG‑Ida chemotherapy followed by reduced‑intensity total‑body irradiation and donor stem cell transplant for adults 60+ with adverse‑risk AML or other high‑grade myeloid cancers

  This trial tests whether FLAG‑Ida chemotherapy given immediately before lower‑intensity total‑body radiation and a donor stem cell transplant can improve outcomes for adults 60 and older with newly diagnosed adverse‑risk acute myeloid leukemia or similar high‑grade myeloid cancers.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT07046078

• Testing STX-0712 in patients with advanced blood cancers

  This study is testing a new drug called STX-0712 to see if it can help people with advanced blood cancers like chronic myelomonocytic leukemia and acute myeloid leukemia who have run out of other treatment options.

  Recruiting at 6 sites Phase 1 Solu Therapeutics, Inc · Stanford, California and 6 other locations · NCT06950034

• Vedolizumab with post-transplant cyclophosphamide and short-course tacrolimus to prevent graft-versus-host disease after reduced-intensity allogeneic stem cell transplant

  This trial tests whether adding vedolizumab to post-transplant cyclophosphamide and a short course of tacrolimus can prevent graft-versus-host disease in adults getting reduced-intensity allogeneic stem cell transplants for leukemias or related blood disorders.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT06815003

• Oral arsenic trioxide plus vitamin C with low-intensity therapy for TP53-mutated AML/MDS/CMML

  This trial will test whether taking oral arsenic trioxide with vitamin C plus a low-intensity drug (a hypomethylating agent, with or without venetoclax) helps adults with TP53-mutated AML, MDS, or CMML who are newly diagnosed or have relapsed/refractory disease.

  Recruiting Phase 2 The University of Hong Kong · Hong Kong · NCT06778187

• Evaluating IMM01 with Azacitidine for Newly Diagnosed Chronic Myelomonocytic Leukemia

  This study is testing if a new treatment combining IMM01 with azacitidine can help people who have just been diagnosed with chronic myelomonocytic leukemia feel better and live longer compared to those getting a placebo with azacitidine.

  Recruiting at 24 sites Phase 3 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. · Hefei, Anhui and 42 other locations · NCT06647862

• Evaluating olutasidenib for patients with specific blood disorders

  This study is testing if a new drug called olutasidenib can help people with certain blood disorders feel better and improve their health.

  Recruiting at 2 sites Phase 2 M.D. Anderson Cancer Center · Miami, Florida and 1 other locations · NCT06566742

• Using olutasidenib to prevent relapse in patients with IDH1 mutated blood cancers after transplant

  This study is testing if a new drug called olutasidenib can help prevent blood cancers from coming back in patients with a specific gene mutation after they have had a stem cell transplant.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California and 1 other locations · NCT06543381

• Axatilimab with or without azacitidine for adults with advanced myeloproliferative neoplasms or high‑risk CMML

  This trial tests whether the antibody axatilimab, alone or together with the chemotherapy azacitidine, can help adults with advanced‑phase myeloproliferative neoplasms, MPN/MDS overlap, or high‑risk chronic myelomonocytic leukemia (CMML).

  Recruiting at 2 sites Phase 1/2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio and 1 other locations · NCT06523556

• Evaluating plasma cytokines in patients with certain blood cancers treated with non-intensive chemotherapy

  This study is trying to see if measuring certain proteins in the blood can help predict how well patients with specific blood cancers do when they receive two different types of chemotherapy.

  Recruiting Nantes University Hospital · Nantes, Loire-Atlantique · NCT06439199

• Restoring gut bacteria before stem cell transplant for blood cancer patients

  This study is testing if restoring gut bacteria with a special treatment before stem cell transplants can help blood cancer patients have better health and treatment outcomes.

  Recruiting at 6 sites Phase 2 Imperial College London · Birmingham, England and 7 other locations · NCT06355583

• Combining Pacritinib and Talazoparib for Patients with Myeloproliferative Neoplasms Not Responding to JAK2 Therapy

  This study is testing a combination of two medications, pacritinib and talazoparib, to see if they can help patients with certain blood cancers who haven't responded to other treatments.

  Recruiting Phase 1 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT06218628

• Using pacritinib with azacitidine for treating chronic myelomonocytic leukemia

  This study is testing if a new combination of two medications, pacritinib and azacitidine, can help people with chronic myelomonocytic leukemia feel better and improve their treatment outcomes.

  Recruiting Phase 1/2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT06159491

• Intensive conditioning for myeloid cancers with extramedullary involvement

  This study is testing a new treatment plan using specific medications before a stem cell transplant to see if it helps people with myeloid cancers that have spread beyond the bone marrow feel better and have better outcomes.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT06111612

• Using Venetoclax with FLAMSA and Treosulfan for Blood Stem Cell Transplantation in Certain Blood Cancers

  This study is testing if a new combination of medications can make blood stem cell transplants safer and more effective for people with certain serious blood cancers.

  Recruiting at 6 sites Phase 1/2 Heinrich-Heine University, Duesseldorf · Aachen, North Rhine-Westphalia and 5 other locations · NCT05807932

• Assessing the safety and effectiveness of LP-108 with azacitidine for blood cancers

  This study is testing a new combination of LP-108 and azacitidine to see if it helps people with blood cancers like acute myeloid leukemia, myelodysplastic syndromes, or chronic myelomonocytic leukemia feel better and stay safe during treatment.

  Recruiting at 3 sites Phase 1 Guangzhou Lupeng Pharmaceutical Company LTD. · Nanchang and 2 other locations · NCT05641259

• Combining new treatments for high-risk blood cancers

  This study is testing a new combination of two treatments for people with high-risk blood cancers to see if it is safe and effective in improving their condition.

  Recruiting at 5 sites Phase 1 Clinical Hub for Interventional Research (CHOIR) · Sydney, New South Wales and 4 other locations · NCT05636514

• Low dose decitabine and venetoclax for treating myeloid cancers

  This study is testing a new lower-dose treatment combining decitabine and venetoclax for patients with myeloid cancers who can't handle the usual medications to see if it's easier for them to tolerate.

  Recruiting at 3 sites Phase 2 Montefiore Medical Center · Sacramento, California and 2 other locations · NCT05184842

• Reduced-intensity conditioning to lower treatment-related mortality in stem cell transplant patients

  This study is testing a new way to prepare patients for a stem cell transplant to see if it can lower the risk of serious treatment-related complications.

  Recruiting Phase 2 Thomas Jefferson University · Philadephia, Pennsylvania · NCT05031897

• Comparing T Cell Depletion Methods for Blood Cancer Treatment

  This study is testing different ways to prevent complications after a stem cell transplant for blood cancer to see which method helps patients stay healthy and cancer-free longer.

  Recruiting at 17 sites Phase 2 University of Birmingham · Cardiff, Wales and 16 other locations · NCT04888741

• Using venetoclax with busulfan to treat high-risk blood cancers

  This study is testing if combining venetoclax with busulfan, cladribine, and fludarabine can help people with high-risk blood cancers like acute myeloid leukemia and myelodysplastic syndrome do better after stem cell transplantation.

  Recruiting Phase 2/3 M.D. Anderson Cancer Center · Houston, Texas · NCT04708054

• Evaluating a new treatment for advanced blood cancers

  This study is testing a new drug called EP0042 to see if it is safe and effective for people with advanced blood cancers like AML, CMML, and MDS.

  Recruiting at 6 sites Phase 1/2 Ellipses Pharma · Perth, Western Australia and 5 other locations · NCT04581512

• Testing a new oral medication for blood cancers

  This study is testing a new oral medication for blood cancers to see if it works better than the standard treatment for patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.

  Recruiting at 65 sites Phase 2/3 Taiho Oncology, Inc. · Los Angeles, California and 72 other locations · NCT04256317

• Treatment of low or intermediate-risk myelodysplastic syndromes and chronic myelomonocytic leukemia with canakinumab

  This study is testing if a new medication called canakinumab can help people with low or intermediate-risk myelodysplastic syndromes and chronic myelomonocytic leukemia feel better and reduce their need for blood transfusions.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT04239157

• Donor stem cell transplant with chemotherapy and radiation for blood cancers

  This study is testing if a donor stem cell transplant combined with different doses of chemotherapy and radiation can help people with blood cancers recover better.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT04195633

• Combining vitamin C with azacitidine for treating higher-risk blood cancers

  This study is testing if adding vitamin C to azacitidine treatment can help people with higher-risk blood cancers feel better and improve their outcomes.

  Recruiting at 8 sites Phase 2 Copenhagen University Hospital, Rigshospitalet · Aalborg and 9 other locations · NCT03999723

• Using hyperbaric oxygen therapy with stem cell transplants

  This study is testing whether hyperbaric oxygen therapy can help patients with chronic leukemias and myelofibrosis who are getting stem cell transplants feel better and recover more effectively.

  Recruiting Early Phase 1 University of Rochester · Rochester, New York · NCT03964506

• Evaluating the safety and effectiveness of tuspetinib in patients with relapsed or refractory acute myeloid leukemia

  This study is testing a new drug called tuspetinib to see if it can safely help people with relapsed or hard-to-treat types of leukemia and related blood disorders.

  Recruiting at 10 sites Phase 1/2 Aptose Biosciences Inc. · Birmingham, Alabama and 33 other locations · NCT03850574

• Using enasidenib and azacitidine to treat patients with recurrent or refractory acute myeloid leukemia and IDH2 gene mutation

  This study is testing if a combination of two medications, enasidenib and azacitidine, can help people with recurrent or hard-to-treat acute myeloid leukemia that has an IDH2 gene mutation.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT03683433

• Using a radioactive antibody followed by stem cell transplant to treat high-risk leukemia or myelodysplastic syndrome

  This study is testing a new radioactive treatment combined with a stem cell transplant to see if it can help people with high-risk leukemia or myelodysplastic syndrome feel better and improve their chances of recovery.

  Recruiting Phase 1/2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT03670966

• Using ascorbic acid with chemotherapy to treat relapsed or refractory lymphoma and related conditions

  This study is testing if adding vitamin C to standard chemotherapy can help people with relapsed or hard-to-treat lymphomas and related blood conditions feel better.

  Recruiting Phase 2 Mayo Clinic · Mankato, Minnesota and 3 other locations · NCT03418038

• Combining azacitidine and enasidenib for treating IDH2-mutant myelodysplastic syndrome

  This study is testing if combining two medications, azacitidine and enasidenib, can help people with IDH2-mutant myelodysplastic syndrome feel better and live longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Baltimore, Maryland and 2 other locations · NCT03383575

• HA-1 TCR T cell therapy for leukemia that returned or didn't respond after a donor stem cell transplant

  This Phase 1 study will test whether giving specially engineered donor T cells called HA-1 TCR T cells is safe and what dose works for people whose acute leukemia came back or didn't respond after a donor stem cell transplant.

  Recruiting Phase 1 Fred Hutchinson Cancer Center · Seattle, Washington · NCT03326921

• Relevance of Peripheral Cells in CMML

  This study looks at how peripheral blood cells relate to chronic myelomonocytic leukemia and how they might help understand the disease in patients being treated at participating centers.

  Recruiting Centre Hospitalier Universitaire de Nice · Nice · NCT03280888

• Using radioactive treatment before stem cell transplant for high-risk leukemia patients

  This study is testing a new radioactive treatment given before a stem cell transplant to see if it can help high-risk leukemia patients by targeting cancer cells while protecting healthy ones.

  Recruiting Phase 1/2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT03128034

• Personalized NK cell therapy after umbilical cord blood transplant for leukemia

  This study is testing if a special treatment using personalized immune cells from umbilical cord blood can help people with leukemia feel better after their transplant.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT02727803

NIH-funded research (10)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Targeted therapies for a blood cancer called CMML (CBL-mutant CMML)

  A physician-scientist is testing targeted drugs to treat a hard-to-kill blood cancer called CMML in patients whose cancer has CBL mutations.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11386695

• Understanding how CMML develops and becomes aggressive

  Looks at blocking overactive MEK/ERK signals and BET protein-driven gene activity to slow or reverse aggressive CMML and lower its chance of turning into AML for people whose leukemia has NRAS and ASXL1 mutations.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11306692

• Blocking PLK1 in RAS‑mutated chronic myelomonocytic leukemia

  People with relapsed or refractory proliferative CMML that has RAS pathway mutations will receive an oral drug called onvansertib that blocks the cell‑division protein PLK1 to look for safety and early signs of benefit.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11304074

• How inflammation changes blood stem cells and drives progression in chronic myelomonocytic leukemia

  Looking at whether inflammation changes blood stem cells and speeds disease in adults with CMML.

  NIH research H. Lee Moffitt Cancer Ctr & Res Inst · Tampa, United States · NIH-11285307

• Patient-based mouse models to find better treatments for chronic myelomonocytic leukemia

  Researchers are using mice implanted with patients' CMML cells to try out new treatment approaches for people with chronic myelomonocytic leukemia.

  NIH research H. Lee Moffitt Cancer Ctr & Res Inst · Tampa, United States · NIH-11179159

• Understanding how chronic myelomonocytic leukemia resists targeted therapy

  This study is looking at how some people with chronic myelomonocytic leukemia (CMML) might not respond to a treatment called cobimetinib, and it aims to help those patients by figuring out why that happens and finding better ways to treat them.

  NIH research University of Utah · Salt Lake City, United States · NIH-11083674

• Targeting a specific protein to treat a type of blood cancer

  This study is looking at a new pill called Onvansertib to see if it can help people with a tough type of blood cancer called chronic myelomonocytic leukemia (CMML) that hasn't responded to other treatments, especially for those with specific gene changes.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11067766

• How inflammation affects blood cell development and disease in chronic myelomonocytic leukemia

  This study is looking at how inflammation affects chronic myelomonocytic leukemia (CMML) and why some patients might see their condition get worse or change into a different type of leukemia, with the hope of finding better ways to manage the disease.

  NIH research H. Lee Moffitt Cancer Ctr & Res Inst · Tampa, United States · NIH-11036287

• New treatments for chronic myelomonocytic leukemia

  This study is looking at chronic myelomonocytic leukemia (CMML) to see how changes in a specific gene affect the disease and how a drug called dasatinib might help treat it, while also figuring out why some patients might not respond to the treatment and what other options could work better together with it.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-10911848

• Creating models to improve treatments for chronic myelomonocytic leukemia

  This study is looking at chronic myelomonocytic leukemia (CMML) to find new treatments by using special models that mimic the disease, and it also explores how a certain type of immune cell might affect how the disease behaves and responds to therapy.

  NIH research H. Lee Moffitt Cancer Ctr & Res Inst · Tampa, United States · NIH-10798431

Related topics

Quick answers

How many Chronic Myelomonocytic Leukemia clinical trials are recruiting right now?

37, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 18 countries. The most sites are in United States (25 trials), United Kingdom (4 trials), Australia (3 trials), France (3 trials), Germany (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 16, Phase 1/2: 7, Phase 1: 6, Phase 2/3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →